GSA CAPITAL PARTNERS LLP

Position in RLMD — Relmada Therapeutics, Inc.

CIK 1362033 LONDON, X0

Position in RLMD

as of Jun 30, 2026 · filed Aug 6, 2026 Compact

Position Value

$978,785

+$842,606 QoQ

Shares Held

141,443

+622.9% QoQ

Ownership

0.133%

of shares outstanding

% of Portfolio

0.07%

of 13F equity value

Holder Rank

#56

of 126 holders

Holding Since

Dec 2021

12 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

GSA CAPITAL PARTNERS LLP holds $104,909,103 across 164 Biotechnology names. RLMD ranks #37 (0.9% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	IOVA	Iovance Biotherapeutics, Inc.	655,318	$2,726,122
2	IMVT	Immunovant, Inc.	65,267	$2,514,737
3	GOSS	Gossamer Bio, Inc.	14,986,947	$2,472,846
4	AXSM	Axsome Therapeutics, Inc.	9,419	$2,305,488
5	CABA	Cabaletta Bio, Inc.	668,563	$2,079,230
6	MLTX	MoonLake Immunotherapeutics	106,695	$2,077,351
7	ATYR	aTYR PHARMA INC	3,454,863	$2,062,553
8	CORT	Corcept Therapeutics Inc	23,257	$2,022,196

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$978,785	141,443	+622.9%	Shares	Sole	2026-08-06
2026-03-31	$136,179	19,566	-84.3%	Shares	Sole	2026-05-08
2024-12-31	$64,881	124,773	+15.1%	Shares	Sole	2025-02-07
2024-09-30	$351,254	108,412	+0.3%	Shares	Sole	2024-11-05
2024-06-30	$324,345	108,115	+4.6%	Shares	Sole	2024-08-15
2024-03-31	$480,442	103,321	-44.0%	Shares	Sole	2024-05-03
2023-12-31	$764,132	184,573	-5.5%	Shares	Sole	2024-02-16
2023-09-30	$586,245	195,415	-28.0%	Shares	Sole	2023-11-15
2023-06-30	$667,949	271,524	+333.8%	Shares	Sole	2023-08-14
2023-03-31	$141,471	62,598	-48.9%	Shares	Sole	2023-05-12
2022-12-31	$427,839	122,590	+603.4%	Shares	Sole	2023-02-13
2021-12-31	$392,675	17,429	—	Shares	Sole	2022-02-14
No filing history on record for this holder in this stock.